MedTrace Logo

Substance Misuse To Psychiatric Disorders for Cannabis

NCT03485274 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2023-07-05

No results posted yet for this study

Summary

With the recent availability of vortioxetine, and the surging phenomenon of cannabis misuses amongst young abusers, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with cannabis use disorders with depressive or anxiety symptoms, to develop into a more chronic disabling dependence or co-morbid state.

Conditions

  • Cannabis Use Disorder
  • Depressive State
  • Anxiety State
  • Depression
  • Anxiety Disorders
  • Pharmacotherapy

Interventions

DRUG

Vortioxetine

oral medication taken once daily

OTHER

Treatment as Usual

Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine

Sponsors & Collaborators

  • Queen Mary Hospital, Hong Kong

    collaborator OTHER

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Albert KK Chung, MBBS(HK) · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-25
Primary Completion
2023-02-28
Completion
2023-04-30
FDA Drug
Yes

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03485274 on ClinicalTrials.gov